Video

Dr. Tagawa on the growing role of radiopharmaceuticals in prostate cancer

Author(s):

Urology Times staff

“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.

In this video, Scott T. Tagawa, MD, MS, FACP, discusses ongoing and upcoming innovation in the radiopharmaceutical space for treatment of prostate cancer, as well as considerations for physicians who are administering these therapies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Related Content
Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617
April 8th 2025

Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

Phillip Kuo, MD, PhD Hannah Clarke
"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates
March 31st 2025

18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

Phillip Kuo, MD, PhD
"I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.
Study finds geographic disparities in MRI use in prostate cancer
March 27th 2025

Study finds geographic disparities in MRI use in prostate cancer

Hannah Clarke
The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.
FDA approves PET imaging product Gozellix for prostate cancer
March 20th 2025

FDA approves PET imaging product Gozellix for prostate cancer

Hannah Clarke
Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke
The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
© 2025 MJH Life Sciences

All rights reserved.